1263-89-4: Neomycin Sulfate EP Impurity E

1263-89-4: Neomycin Sulfate EP Impurity E

Also known as Aminosidine Sulfate, it is an impurity present in Neomycin that is bactericidal in vitro against a wide variety of gram-negative and gram-positive organisms, including some that are streptomycin-resistant, and also it is utilized in dermatological therapy.

Additional information on CAS 1263-89-4

Catalogue No.

VE006931
CAS No.

1263-89-4
Molecular Formula

C23H45N5O14 . H2SO4
Molecular Weight

615.63 . 98.07
Parent drug

Neomycin
IUPAC Name

(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol sulfate
Synonyms

Aminosidine Sulfate
References

Szychowski, Janek, et al. “Inhibition of Aminoglycoside-Deactivating Enzymes APH(3?)-IIIa and AAC(6?)-Ii by Amphiphilic Paromomycin O2??-Ether Analogues.” ChemMedChem, vol. 6, no. 11, Sept. 2011, pp. 1961–66, https://doi.org/10.1002/cmdc.201100346 Kile, Roy L. “USE of NEOMYCIN in DERMATOLOGY.” JAMA: The Journal of the American Medical Association, vol. 148, no. 5, Feb. 1952, p. 339, https://doi.org/10.1001/jama.1952.02930050011003.?
Status

In-stock

Other products related to neomycin

[rfq_list]

Login first to add product to RFQ List

Request a quote

1263-89-4: Neomycin Sulfate EP Impurity E

1263-89-4: Neomycin Sulfate EP Impurity E
Catalogue No.

VE006931
CAS No.

1263-89-4
Molecular Formula

C23H45N5O14 . H2SO4
Molecular Weight

615.63 . 98.07
Parent drug

Neomycin
IUPAC Name

(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol sulfate
Synonyms

Aminosidine Sulfate
References

Szychowski, Janek, et al. “Inhibition of Aminoglycoside-Deactivating Enzymes APH(3?)-IIIa and AAC(6?)-Ii by Amphiphilic Paromomycin O2??-Ether Analogues.” ChemMedChem, vol. 6, no. 11, Sept. 2011, pp. 1961–66, https://doi.org/10.1002/cmdc.201100346 Kile, Roy L. “USE of NEOMYCIN in DERMATOLOGY.” JAMA: The Journal of the American Medical Association, vol. 148, no. 5, Feb. 1952, p. 339, https://doi.org/10.1001/jama.1952.02930050011003.?
Status

In-stock
ListName

Neomycin Sulfate EP Impurity E
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden